• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

曼努埃尔家族中与 Glanzmann 血小板无力症相关的法国吉普赛突变的 founder 效应及年龄估计。

Founder effect and estimation of the age of the French Gypsy mutation associated with Glanzmann thrombasthenia in Manouche families.

机构信息

Centre de Référence des Pathologies Plaquettaires, Plateforme Technologique d'Innovation Biomédicale, Hôpital Xavier Arnozan, Pessac, France.

出版信息

Eur J Hum Genet. 2011 Sep;19(9):981-7. doi: 10.1038/ejhg.2011.61. Epub 2011 Apr 13.

DOI:10.1038/ejhg.2011.61
PMID:21487445
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3179361/
Abstract

The c.1544+1G>A substitution at the 5' splice donor site of intron 15 of the ITGA2B gene, called the French Gypsy mutation, causes Glanzmann thrombasthenia, an inherited hemorrhagic disorder transmitted as an autosomal recessive trait and characterized by an altered synthesis of the platelet αIIbβ3 integrin. So far, this mutation has only been found in affected individuals originating from French Manouche families, strongly suggesting a founder effect. Our goal was to investigate the origin of the French Gypsy mutation. We estimated the age of the mutation by a likelihood-based method that uses the length of the shared haplotypes among a set of patients. For this, we genotyped 23 individuals of Manouche origin; consisting of 9 Glanzmann thrombasthenia patients homozygous for the French Gypsy mutation, 6 heterozygous carriers and 8 homozygous wild-type individuals. They were genotyped for four single-nucleotide polymorphisms using high-resolution melting curve analysis, and for two CA repeats in the BRCA1 and THRA genes at chromosome 17, using fragment analysis gels. We found that a haplotype of five polymorphic loci covering a 4-cM region was strongly associated with the French Gypsy mutation, suggesting a founder effect. The estimated age of this founder mutation was 300-400 years (range 255-552 years). Thus, all carriers of the French Gypsy mutation c.1544+1G>A at intron 15 descended from a common ancestor 300-400 years ago.

摘要

该 c.1544+1G>A 取代在 5' 剪接供体位点的内含子 15 的 ITGA2B 基因,称为法国吉普赛突变,导致 Glanzmann 血小板无力症,一种遗传性出血性疾病作为常染色体隐性遗传特征和 αIIbβ3 血小板整合素的改变的合成。到目前为止,这种突变只在来自法国吉普赛家庭的受影响个体中发现,强烈提示存在一个奠基者效应。我们的目标是研究法国吉普赛突变的起源。我们通过使用一组患者之间共享单倍型的长度的基于可能性的方法来估计突变的年龄。为此,我们对 23 名 Manouche 血统的个体进行了基因分型;包括 9 名 Glanzmann 血小板无力症患者,纯合子法国吉普赛突变,6 名杂合子携带者和 8 名纯合野生型个体。他们使用高分辨率熔解曲线分析对四个单核苷酸多态性进行基因分型,并且在染色体 17 上的 BRCA1 和 THRA 基因中的两个 CA 重复,使用片段分析凝胶。我们发现,覆盖 4-cM 区域的五个多态性位点的单倍型与法国吉普赛突变强烈相关,提示存在奠基者效应。该奠基突变的估计年龄为 300-400 岁(范围 255-552 岁)。因此,所有 5' 剪接供体位点的 c.1544+1G>A 法国吉普赛突变的携带者都来自 300-400 年前的共同祖先。

相似文献

1
Founder effect and estimation of the age of the French Gypsy mutation associated with Glanzmann thrombasthenia in Manouche families.曼努埃尔家族中与 Glanzmann 血小板无力症相关的法国吉普赛突变的 founder 效应及年龄估计。
Eur J Hum Genet. 2011 Sep;19(9):981-7. doi: 10.1038/ejhg.2011.61. Epub 2011 Apr 13.
2
Immunization against α β and α β in Glanzmann thrombasthenia patients carrying the French Gypsy mutation.针对携带法国吉普赛突变的 Glanzmann 血小板无力症患者的 α β 和 α β 免疫。
J Thromb Haemost. 2021 Jan;19(1):255-261. doi: 10.1111/jth.15117. Epub 2020 Nov 18.
3
Expanding the Mutation Spectrum Affecting αIIbβ3 Integrin in Glanzmann Thrombasthenia: Screening of the ITGA2B and ITGB3 Genes in a Large International Cohort.扩大Glanzmann血小板无力症中影响αIIbβ3整合素的突变谱:在一个大型国际队列中对ITGA2B和ITGB3基因进行筛查
Hum Mutat. 2015 May;36(5):548-61. doi: 10.1002/humu.22776.
4
Natural history of platelet antibody formation against αIIbβ3 in a French cohort of Glanzmann thrombasthenia patients.法国血小板无力症患者队列中αIIbβ3 血小板抗体形成的自然史。
Haemophilia. 2012 May;18(3):e201-9. doi: 10.1111/j.1365-2516.2011.02744.x. Epub 2012 Jan 18.
5
Glanzmann thrombasthenia caused by an 11.2-kb deletion in the glycoprotein IIIa (beta3) is a second mutation in Iraqi Jews that stemmed from a distinct founder.由糖蛋白IIIa(β3)中11.2 kb缺失引起的Glanzmann血小板无力症是伊拉克犹太人中的第二种突变,起源于一个独特的奠基者。
Blood. 1997 May 15;89(10):3654-62.
6
Glycoprotein IIb Leu214Pro mutation produces glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa.糖蛋白IIb亮氨酸214脯氨酸突变导致血小板无力症,伴有糖蛋白IIb/IIIa的数量和质量异常。
Blood. 1998 Mar 1;91(5):1562-71.
7
Analysis of platelet membrane glycoprotein polymorphisms in Glanzmann thrombasthenia showed the French gypsy mutation in the alphaIIb gene to be strongly linked to the HPA-1b polymorphism in beta3.对血小板无力症患者血小板膜糖蛋白多态性的分析表明,αIIb基因中的法国吉普赛人突变与β3中的HPA-1b多态性紧密相关。
J Thromb Haemost. 2003 Mar;1(3):573-5. doi: 10.1046/j.1538-7836.2003.00107.x.
8
Disulfide bond disruption by a beta 3-Cys549Arg mutation in six Jordanian families with Glanzmann thrombasthenia causes diminished production of constitutively active alpha IIb beta 3.在六个患有Glanzmann血小板无力症的约旦家族中,β3-Cys549Arg突变导致的二硫键破坏会使组成型活性αIIbβ3的产生减少。
Thromb Haemost. 2007 Dec;98(6):1257-65.
9
Abnormal cytoplasmic extensions associated with active αIIbβ3 are probably the cause for macrothrombocytopenia in Glanzmann thrombasthenia-like syndrome.与活化的αIIbβ3相关的异常细胞质延伸可能是Glanzmann血小板无力症样综合征中巨血小板减少症的病因。
Blood Coagul Fibrinolysis. 2015 Apr;26(3):302-8. doi: 10.1097/MBC.0000000000000241.
10
Prenatal diagnosis of Glanzmann thrombasthenia using the polymorphic markers BRCA1 and THRA1 on chromosome 17.
Br J Haematol. 1998 Jul;102(2):582-7. doi: 10.1046/j.1365-2141.1998.00798.x.

引用本文的文献

1
characterization of rare anti-αβ isoantibodies produced by patients with Glanzmann thrombasthenia that severely block fibrinogen binding and generate procoagulant platelets via complement activation.对患有Glanzmann血小板无力症的患者产生的罕见抗αβ同种抗体的表征,这些抗体严重阻断纤维蛋白原结合并通过补体激活产生促凝血小板。
Res Pract Thromb Haemost. 2023 Nov 4;8(1):102253. doi: 10.1016/j.rpth.2023.102253. eCollection 2024 Jan.
2
Profiling the Genetic and Molecular Characteristics of Glanzmann Thrombasthenia: Can It Guide Current and Future Therapies?剖析血小板无力症的遗传和分子特征:它能否指导当前及未来的治疗?
J Blood Med. 2021 Jul 8;12:581-599. doi: 10.2147/JBM.S273053. eCollection 2021.
3
A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer.在甲状腺癌的葡萄牙罗姆患者中, CHEK2 的致病变异表现出明显的创始效应。
Endocrine. 2021 Sep;73(3):588-597. doi: 10.1007/s12020-021-02660-x. Epub 2021 Mar 8.
4
Specifications of the variant curation guidelines for ITGA2B/ITGB3: ClinGen Platelet Disorder Variant Curation Panel.ITGA2B/ITGB3变异评估指南规范:临床基因组资源血小板疾病变异评估小组
Blood Adv. 2021 Jan 26;5(2):414-431. doi: 10.1182/bloodadvances.2020003712.
5
Glanzmann thrombasthenia in Pakistan: molecular analysis and identification of novel mutations.巴基斯坦的Glanzmann血小板无力症:新突变的分子分析与鉴定
Clin Genet. 2016 Feb;89(2):187-92. doi: 10.1111/cge.12622. Epub 2015 Jul 15.
6
αIIbβ3 variants defined by next-generation sequencing: predicting variants likely to cause Glanzmann thrombasthenia.通过下一代测序定义的αIIbβ3变体:预测可能导致Glanzmann血小板无力症的变体。
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):E1898-907. doi: 10.1073/pnas.1422238112. Epub 2015 Mar 31.
7
Glanzmann thrombasthenia: state of the art and future directions.《Glanzmann 血小板无力症:最新进展和未来方向》
Semin Thromb Hemost. 2013 Sep;39(6):642-55. doi: 10.1055/s-0033-1353393. Epub 2013 Aug 8.
8
Clinical utility gene card for: Glanzmann thrombasthenia.血小板无力症临床实用基因卡片
Eur J Hum Genet. 2012 Oct;20(10). doi: 10.1038/ejhg.2012.151. Epub 2012 Jul 11.

本文引用的文献

1
Rapid diagnosis of the French gypsy mutation in Glanzmann thrombasthenia using high-resolution melting analysis.
Thromb Haemost. 2010 Nov;104(5):1076-7. doi: 10.1160/TH10-05-0268. Epub 2010 Sep 30.
2
Disulfide bond disruption by a beta 3-Cys549Arg mutation in six Jordanian families with Glanzmann thrombasthenia causes diminished production of constitutively active alpha IIb beta 3.在六个患有Glanzmann血小板无力症的约旦家族中,β3-Cys549Arg突变导致的二硫键破坏会使组成型活性αIIbβ3的产生减少。
Thromb Haemost. 2007 Dec;98(6):1257-65.
3
Family screening for a Glanzmann's thrombasthenia mutation using PCR-SSCP.
Platelets. 1998;9(2):129-36. doi: 10.1080/09537109876915.
4
Glanzmann thrombasthenia.血小板无力症
Orphanet J Rare Dis. 2006 Apr 6;1:10. doi: 10.1186/1750-1172-1-10.
5
A 13-bp deletion in alpha(IIb) gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia.α(IIb)基因中的13个碱基对缺失是一种奠基者突变,在患有Glanzmann血小板无力症的巴勒斯坦阿拉伯患者中占主导地位。
J Thromb Haemost. 2005 Dec;3(12):2764-72. doi: 10.1111/j.1538-7836.2005.01618.x.
6
Mutation history of the roma/gypsies.罗姆人/吉普赛人的突变史。
Am J Hum Genet. 2004 Oct;75(4):596-609. doi: 10.1086/424759. Epub 2004 Aug 20.
7
The International HapMap Project.国际人类基因组单体型图计划
Nature. 2003 Dec 18;426(6968):789-96. doi: 10.1038/nature02168.
8
Detecting population growth, selection and inherited fertility from haplotypic data in humans.从人类单倍型数据中检测群体增长、选择和遗传生育力。
Genetics. 2003 Nov;165(3):1579-86. doi: 10.1093/genetics/165.3.1579.
9
Rebuttal: the French Gypsy mutation does not give rise to a particularly mild form of Glazmann's thrombasthenia.反驳:法国吉普赛人突变不会引发特别轻微形式的Glazmann血小板无力症。
J Thromb Haemost. 2003 Nov;1(11):2459. doi: 10.1046/j.1538-7836.2003.0468g.x.
10
Analysis of platelet membrane glycoprotein polymorphisms in Glanzmann thrombasthenia showed the French gypsy mutation in the alphaIIb gene to be strongly linked to the HPA-1b polymorphism in beta3.对血小板无力症患者血小板膜糖蛋白多态性的分析表明,αIIb基因中的法国吉普赛人突变与β3中的HPA-1b多态性紧密相关。
J Thromb Haemost. 2003 Mar;1(3):573-5. doi: 10.1046/j.1538-7836.2003.00107.x.